Mohsen Rajabnia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mohsen Rajabnia has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
Mahsa Mohammadi
Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran
5 shared publicationsFatemeh Bastan
Student Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
4 shared publicationsKhaled Rahmani
Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran
4 shared publicationsSeyyed Nima Naleini
Student Research Committee, Kurdistan University of Medical Sciences, Sanandaj, Iran
4 shared publicationsMahmood Bakhtiyari
Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran
3 shared publicationsMaryam Rashidian
Student Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
3 shared publications
Latest Publications
- Open Access
Evaluation of Large Language Models in the Clinical Management of Patients With Upper Gastrointestinal Bleeding : Insights From Real-World Patient Data
Objective Upper gastrointestinal bleeding (UGIB) is a life-threatening emergency requiring rapid risk assessment. Current scoring tools have limited accuracy. Large language models (LLMs) may support clinical decision-making, but their role in UGIB management is unclear. This study evaluated LLMs for patient risk classification, prediction of endoscopic findings, and alignment with routine clinical decision-making. Methods In this retrospective study, we analyzed electronic health records(EHRs) of 384 UGIB patients presented to two referral centers in Karaj, Iran, between March and December 2024. Included cases underwent upper gastrointestinal endoscopy; incomplete records were excluded. Five LLMs including GPT-5, Llama 4, Gemini-2.5-Flash, DeepSeek R1, and Grok were assessed using in-context learning for (i) risk classification, (ii) prediction of probable endoscopic findings, and (iii) clinical justification generation. Performance metrics included accuracy, precision, recall, and F1-score, compared with conventional machine learning models. Two gastroenterologists independently assessed justifications across seven domains: relevance, clarity, originality, completeness, specificity, correctness, and consistency. Results All LLMs outperformed conventional models (highest baseline accuracy 0.54). GPT-5 achieved the highest risk classification accuracy (0.66), followed by Llama 4 (0.64). Grok performed best in predicting endoscopic findings (0.32). gastroenterologists noted variability in reasoning: GPT-5 and Grok provided the most complete justifications, though GPT-5 occasionally over-classified urgent cases. Llama-4 and Gemini-2.5-Flash were less specific, while DeepSeek R1 offered detailed patient summaries but lacked predictive outputs. Conclusions LLMs improved UGIB risk prediction and generate interpretive reasoning, but accuracy limitations, inconsistent reasoning, and occasional risk misclassification highlight the need for clinician oversight and prospective validation before clinical use. What is already known on this topic UGIB is a medical emergency requiring rapid risk stratification and timely management. LLMs are promising tools for clinical decision support, but their role in UGIB management remains unclear. What this study adds LLMs can improve risk prediction and interpretive reasoning in UGIB, but limitations in accuracy, inconsistent reasoning, and occasional misclassification highlight the need for clinician oversight and prospective validation. How this study might affect research, practice, or policy LLMs provide structured, human-readable explanations that could support clinical decision-making, potentially reduce unnecessary emergency endoscopies, improve care efficiency, and alleviate physician workload.
Open AccessEvaluation of Large Language Models in the Clinical Management of Patients With Upper Gastrointestinal Bleeding : Insights From Real-World Patient Data
Objective Upper gastrointestinal bleeding (UGIB) is a life-threatening emergency requiring rapid risk assessment. Current scoring tools have limited accuracy. Large language models (LLMs) may support clinical decision-making, but their role in UGIB management is unclear. This study evaluated LLMs for patient risk classification, prediction of endoscopic findings, and alignment with routine clinical decision-making. Methods In this retrospective study, we analyzed electronic health records(EHRs) of 384 UGIB patients presented to two referral centers in Karaj, Iran, between March and December 2024. Included cases underwent upper gastrointestinal endoscopy; incomplete records were excluded. Five LLMs including GPT-5, Llama 4, Gemini-2.5-Flash, DeepSeek R1, and Grok were assessed using in-context learning for (i) risk classification, (ii) prediction of probable endoscopic findings, and (iii) clinical justification generation. Performance metrics included accuracy, precision, recall, and F1-score, compared with conventional machine learning models. Two gastroenterologists independently assessed justifications across seven domains: relevance, clarity, originality, completeness, specificity, correctness, and consistency. Results All LLMs outperformed conventional models (highest baseline accuracy 0.54). GPT-5 achieved the highest risk classification accuracy (0.66), followed by Llama 4 (0.64). Grok performed best in predicting endoscopic findings (0.32). gastroenterologists noted variability in reasoning: GPT-5 and Grok provided the most complete justifications, though GPT-5 occasionally over-classified urgent cases. Llama-4 and Gemini-2.5-Flash were less specific, while DeepSeek R1 offered detailed patient summaries but lacked predictive outputs. Conclusions LLMs improved UGIB risk prediction and generate interpretive reasoning, but accuracy limitations, inconsistent reasoning, and occasional risk misclassification highlight the need for clinician oversight and prospective validation before clinical use. What is already known on this topic UGIB is a medical emergency requiring rapid risk stratification and timely management. LLMs are promising tools for clinical decision support, but their role in UGIB management remains unclear. What this study adds LLMs can improve risk prediction and interpretive reasoning in UGIB, but limitations in accuracy, inconsistent reasoning, and occasional misclassification highlight the need for clinician oversight and prospective validation. How this study might affect research, practice, or policy LLMs provide structured, human-readable explanations that could support clinical decision-making, potentially reduce unnecessary emergency endoscopies, improve care efficiency, and alleviate physician workload.
- Open Access
- 26 August 2025
- Vol. 18 (3) , 286-300
Upper gastrointestinal endoscopy: evolving classification tools
Gastrointestinal (GI) endoscopy is a fundamental tool for diagnosing and managing digestive diseases. Standardized classification systems have enhanced the consistency, accuracy, and clinical decision-making in endoscopic evaluation. This review explores key classification systems, their applications, and challenges in their implementation (1).
- 26 August 2025
- Vol. 18 (3) , 286-300
Open AccessUpper gastrointestinal endoscopy: evolving classification tools
Gastrointestinal (GI) endoscopy is a fundamental tool for diagnosing and managing digestive diseases. Standardized classification systems have enhanced the consistency, accuracy, and clinical decision-making in endoscopic evaluation. This review explores key classification systems, their applications, and challenges in their implementation (1).
- Open Access
- 9 August 2025
- Published by Wiley
Foreign Body Ingestion in the Upper Gastrointestinal Tract: A Comprehensive Review of Guidelines and Endoscopic Management with Case Presentations
- 9 August 2025
- Published by Wiley
Open AccessForeign Body Ingestion in the Upper Gastrointestinal Tract: A Comprehensive Review of Guidelines and Endoscopic Management with Case Presentations
- Open Access
- 31 July 2025
- Published by Elsevier in Surgery Open Science
- Vol. 27, 99-103
S-EMR: A first experience with stalked endoscopic mucosal resection in thick and high-risk pedunculated polyps
- 31 July 2025
- Published by Elsevier in Surgery Open Science
- Vol. 27, 99-103
Open AccessS-EMR: A first experience with stalked endoscopic mucosal resection in thick and high-risk pedunculated polyps
- Open Access
- 2 May 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1
Correction: The prevalence of Barrett ‘s esophagus in Iranian patients with gastrointestinal symptoms: a systematic review and meta-analysis
- 2 May 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1
Open AccessCorrection: The prevalence of Barrett ‘s esophagus in Iranian patients with gastrointestinal symptoms: a systematic review and meta-analysis
- Open Access
- 2 April 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-9
The prevalence of Barrett ‘s esophagus in Iranian patients with gastrointestinal symptoms: a systematic review and meta-analysis
Barrett’s esophagus (BE) is a premalignant columnar metaplasia of the esophagus that predisposes victims to esophageal adenocarcinoma (EAC). Depending on differences in the study population and risk factors, the prevalence of BE may vary, from 0.4 to 20% globally. The current study aimed to systematically review and analyse the prevalence of BE in in patients with gastrointestinal symptoms in Iran. Furthermore, gastrointestinal malignancies are among the most common tumours in Iran, making this study even more significant. A systematic search was carried out in PubMed, Web of Science, Scopus, and EMBASE as well as some domestic databases including SID, Magiran, IranDoc, IranMedex from inception to the end of 2023. We included all cross-sectional studies which reported the prevalence of BE and calculated pooled prevalence. The results of the analysis, including 9 studies in a total of 4978 cases (213 Barret diagnoses), revealed that by the results of these studies, the prevalence of Barret’s esophagus is 4.4% [I2 = 94.9% [92.2%; 96.6%]/p-value < 0.0001]. Subgroup analysis, divided by region and year, revealed significant differences between groups. The epidemiology of BE in Iran is not completely identified. This is the first systematic review and meta-analysis evaluating the prevalence and of BE in Iran. Due to the importance of BE in progressing to esophageal adenocarcinoma, much importance should be given to its timely diagnosis. It is strongly recommended to conduct more comprehensive studies including more patients in this field.
- 2 April 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-9
Open AccessThe prevalence of Barrett ‘s esophagus in Iranian patients with gastrointestinal symptoms: a systematic review and meta-analysis
Barrett’s esophagus (BE) is a premalignant columnar metaplasia of the esophagus that predisposes victims to esophageal adenocarcinoma (EAC). Depending on differences in the study population and risk factors, the prevalence of BE may vary, from 0.4 to 20% globally. The current study aimed to systematically review and analyse the prevalence of BE in in patients with gastrointestinal symptoms in Iran. Furthermore, gastrointestinal malignancies are among the most common tumours in Iran, making this study even more significant. A systematic search was carried out in PubMed, Web of Science, Scopus, and EMBASE as well as some domestic databases including SID, Magiran, IranDoc, IranMedex from inception to the end of 2023. We included all cross-sectional studies which reported the prevalence of BE and calculated pooled prevalence. The results of the analysis, including 9 studies in a total of 4978 cases (213 Barret diagnoses), revealed that by the results of these studies, the prevalence of Barret’s esophagus is 4.4% [I2 = 94.9% [92.2%; 96.6%]/p-value < 0.0001]. Subgroup analysis, divided by region and year, revealed significant differences between groups. The epidemiology of BE in Iran is not completely identified. This is the first systematic review and meta-analysis evaluating the prevalence and of BE in Iran. Due to the importance of BE in progressing to esophageal adenocarcinoma, much importance should be given to its timely diagnosis. It is strongly recommended to conduct more comprehensive studies including more patients in this field.
- Open Access
- 27 October 2024
- Published by Wiley
A rare case of colonic mixed neuroendocrine -non neuroendocrine neoplasm (MiNEN) treatment by Cisplatin-Etoposide
A rare case of colonic mixed neuroendocrine -non neuroendocrine neoplasm (MiNEN) treatment by Cisplatin-Etoposide
- 27 October 2024
- Published by Wiley
Open AccessA rare case of colonic mixed neuroendocrine -non neuroendocrine neoplasm (MiNEN) treatment by Cisplatin-Etoposide
A rare case of colonic mixed neuroendocrine -non neuroendocrine neoplasm (MiNEN) treatment by Cisplatin-Etoposide
- Open Access
- 1 May 2024
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2024 (5) , omae039
Rectal gastrointestinal stromal tumor (GIST) in a patient with Crohn’s disease: a rare coincidence case report and brief literature review
Gastrointestinal stromal tumors (GISTs) are the most common type of gastrointestinal mesenchymal tumors. The most common site for developing these neoplasms is the stomach and small intestine. In contrast, anorectal GISTs are very rare. Population-based studies have shown an increased risk of colorectal cancers (CRC) in patients with Crohn’s disease (CD). As in sporadic CRC, adenocarcinomas are the most commonly observed tumor. Accordingly, it is expected that rectal mass in CD patients to be an adenocarcinoma. Some reports have presented CD cases with GISTs along the gastrointestinal tract; however, to the best of our knowledge, a rectal GIST has not been reported in CD. Herein, we report a 41-year-old woman with CD who presented with 8 weeks of constipation and was diagnosed with rectal GIST and briefly review existing reports regarding GIST in IBD.
- 1 May 2024
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2024 (5) , omae039
Open AccessRectal gastrointestinal stromal tumor (GIST) in a patient with Crohn’s disease: a rare coincidence case report and brief literature review
Gastrointestinal stromal tumors (GISTs) are the most common type of gastrointestinal mesenchymal tumors. The most common site for developing these neoplasms is the stomach and small intestine. In contrast, anorectal GISTs are very rare. Population-based studies have shown an increased risk of colorectal cancers (CRC) in patients with Crohn’s disease (CD). As in sporadic CRC, adenocarcinomas are the most commonly observed tumor. Accordingly, it is expected that rectal mass in CD patients to be an adenocarcinoma. Some reports have presented CD cases with GISTs along the gastrointestinal tract; however, to the best of our knowledge, a rectal GIST has not been reported in CD. Herein, we report a 41-year-old woman with CD who presented with 8 weeks of constipation and was diagnosed with rectal GIST and briefly review existing reports regarding GIST in IBD.